Track topics on Twitter Track topics that are important to you
Global Biosimilars Market Research Report Forecast 2017 2022 PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Global Biosimilars Market Research Report Forecast 2017 2022 articles that have been published worldwide.
We have published hundreds of Global Biosimilars Market Research Report Forecast 2017 2022 news stories on BioPortfolio along with dozens of Global Biosimilars Market Research Report Forecast 2017 2022 Clinical Trials and PubMed Articles about Global Biosimilars Market Research Report Forecast 2017 2022 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Global Biosimilars Market Research Report Forecast 2017 2022 Companies in our database. You can also find out about relevant Global Biosimilars Market Research Report Forecast 2017 2022 Drugs and Medications on this site too.
As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and su...
Created via the Biologics Price Competition and Innovation Act, the biosimilar class of drugs was conceived as an opportunity to introduce competition for commonly used biologics following loss of patent protection and market exclusivity, similar to the generic paradigm that has helped sustain access and innovation for more than 3 decades. The FDA approves a biosimilar after a manufacturer establishes that the product is highly similar to a previously approved originator biologic reference product without a...
Market timing is an investment technique that tries to continuously switch investment into assets forecast to have better returns. What is the likelihood of having a successful market timing strategy? With an emphasis on modeling simplicity, I calculate the feasible set of market timing portfolios using index mutual fund data for perfectly timed (by hindsight) all or nothing quarterly switching between two asset classes, US stocks and bonds over the time period 1993-2017. The historical optimal timing path ...
The 2017 International Forum on Gonococcal Infections and Resistance (2017 IFGIR) was held at Shenzhen, China from 17 to 19 September 2017. The key objectives were to gather experts in the field to review and analyze the epidemiological profiles of gonococcal infections and antimicrobial resistance (AMR) at global, regional and national levels; to share and discuss findings from ongoing and completed research studies; and to identify research needs to respond to the spread of gonococcal infections and AMR. ...
The Global Virus Network (GVN) was established in 2011 to strengthen research and responses to emerging viral causes of human disease and to prepare against new viral pandemics. There are now 40 GVN Centers of Excellence and 6 Affiliate laboratories in 24 countries. The 2017 meeting was held from September 25-27 in Melbourne, Australia, and was hosted by the Peter Doherty Institute for Infection and Immunity and the Institut Pasteur. This report highlights the recent accomplishments of GVN researchers in se...
There are now 10 approved biosimilars in the United States, including 3 oncology drugs, and at least 16 others in late-stage development. The introduction of competition into the biologic space launches a new era in the treatment of cancer, possibly increasing access to the extremely costly biologics. The most important and influential stakeholders for biosimilar acceptance and usage are healthcare providers, such as pharmacists and physicians, as well as patients. Gaining their support requires extensive e...
Of the key technologies listed as "ready to propel industries and transform our world" in the 2017 report Top 50 Emerging Technologies: Growth Opportunities of Strategic Imperative, most fall under the scope of biomedical engineering (BME). Issued by the major market research and analysis company Frost and Sullivan , the report's findings are no surprise to the researchers, clinicians, and others who are heavily invested in this field.
Medication non-adherence is a worldwide problem. The aim of this study was to assess the global research output, research trends and topics that shaped medication adherence research.
BRICS, the acronym for Brazil, Russia, India, China and South Africa, is the first multilateral group created and run by non-western developed countries. The group aims to influence world geopolitics and market based on the right of developing and emerging countries to participate equitably in development. The social issue lies at the core of the group's justifications to achieve its goals. In this regard, this paper aims to analyze how the social issue has been addressed by BRICS. The methodology was based...
The Sino-Austrian High-Tech Acupuncture Research Network was founded in 2005 and has been growing ever since. The network comprises many partners from China and is highly involved in research and education activities. This report introduces the network's activities in the year 2017.
Considerable research has been done on the complex stock market, however, there is very little systematic work on the impact of crisis on global stock markets. For filling in these gaps, we propose a complex network method, which analyzes the effects of the 2008 global financial crisis on global main stock index from 2005 to 2010. Firstly, we construct three weighted networks. The physics-derived technique of minimum spanning tree is utilized to investigate the networks of three stages. Regional clustering ...
As the second largest pharmaceutical market with a great potential for future growth, China has drawn much attention from the global pharmaceutical community. With an increasing government investment in biomedical research, the domestic biopharmaceutical (biotechnological) companies in China are turning their attention to the development of innovative medicines and targeting the global market. To introduce innovative products to Chinese patients sooner, to improve the efficiency of its review and approval p...
Biosimilars are biological medicines that are analogues of a specific reference product. Biosimilars of the tumor necrosis factor alpha inhibitors infliximab and etanercept are already approved and available for dermatological indications. Regulatory agencies require in-depth analysis of physicochemical and functional properties of these highly complex molecules as well as clinical data on their similarity regarding efficacy and safety in at least one clinical trial in a sensitive and homogeneous population...
The Global Emergency Medicine Literature Review (GEMLR) conducts an annual search of peer-reviewed and gray literature relevant to global emergency medicine (EM) to identify, review, and disseminate the most important new research in this field to a global audience of academics and clinical practitioners.
Because physicians and health plan members both value choice, the current weak market for Inflectra and Renflexis could be a passing phase. Attitudes could change once there is more data that show people do well after switching from Remicade to the newcomers.
The Australian Sentinel Practices Research Network was established in 1991 to provide a rapid, national, monitoring scheme for infectious diseases that can alert public health officials of epidemics before they arise. The network consists of general practitioners, throughout all 8 states and territories in Australia, who report presentations on a number of defined medical conditions each week. This report presents data from the 1st quarter of 2017 (1 January to 31 March) and includes the syndromic surveilla...
To evaluate the possibility that switching from reference biologic medicines to biosimilars could lead to altered clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy for patients, a systematic literature review was conducted of all switching studies between related biologics (including biosimilars).
Availability of biologic disease-modifying antirheumatic drugs (bDMARDs) has improved clinical outcomes in rheumatoid arthritis, but it also increased the cost of treatment. Biosimilars, the regulated copies of biologic products, have a potential to reduce health care costs and expand access to treatment. However, because of a complex development process, biosimilars can be considered only those noninnovator biologics with satisfactory supporting evidence (ranging from structural to clinical), as outlined i...
The objective of this study was to assess global research output in the field of PET and to provide a general picture of PET research.
Substandard and falsified medical products are a public health threat, primarily associated with low- and middle-income countries. Today, the phenomenon also exists in high-income countries. Increased Internet access has opened a global market. Self-diagnosis and self-prescription have boosted the market for unregulated websites with access to falsified medicines.
Tobacco Heating System 2.2 (THS 2.2, marketed as iQOS), is a heat-not-burn (HNB) tobacco product that has been successfully introduced to global markets. Despite its expanding market, few independent and systematic researches into THS 2.2 have been carried out to date.
The nocebo effect is defined as a negative effect of a pharmacological or non-pharmacological medical treatment that is induced by patients' expectations, and that is unrelated to the physiological action of the treatment. The nocebo effect is an important clinical challenge in the current era of biosimilars. Areas covered: This review aims to answer five key questions about the nocebo effect, namely to reveal its definition, pathophysiology, clinical relevance, contributing factors, and management. Expert ...